PSMA agent, accounts. competing number sequential approval of PYLARIFY existing the PET our XX.X% of additional remain sequential We everyone. delivered driven enable Leading advantages million, quarter with of with Thank Lantheus our PYLARIFY, sustainable is majority the of first and sales from growth agents. believe PSMA way XXXX, offers competitive by growth which even the Anne, with the will that and imaging morning, Mary the vast to approximately you, year-over-year representing $XXX.X growth good one for it X%
only biochemical enrolled being patients with management includes having a change the results measured scientific journal. in been differentiation to of patient have study intended clinical a PET or imaging PYLARIFY’s PSMA for BCR registrational recurrence peer-reviewed in published XX% agent in
which had two-thirds nearly interpretation conventional demonstrated intra-reader a scanned with of in with we that being high high CONDOR agreement negative PYLARIFY PYLARIFY. PET change very to confidence BCR after believe Our intended management inclusion study patients PYLARIFY the provides results of consistent in pivotal or also intern demonstrated PSMA scans. equivocal at with Phase III and imaging
Scientific image used other advantages in clarity PET isotopes versus supports imaging. literature FXXs PSMA broadly
and all studies KOL scientific value differentiated with demonstrates the pivotal of research, guidelines, feedback clinical Our PSMA PET PYLARIFY.
a PYLARIFY access, also adoption payer the and team as both commercial and transitional XXX,XXX by multi-partner geographically including and than academic dedicated supply more launch. pass-through commercial significant diverse has since largest sustain PYLARIFY partners PMF performed the supply reliability. Broad scans network, including status, demonstrated
we more flexible two-hour imaging minutes or Medicare CMS, offers for time and dose radiopharmaceuticals XX nearly for the payment promising There a comments versus separate XXXX, products, advantages recently the as for requested status. payment the of for and for first Medicaid Centers transitional been proposed administration has forth PYLARIFY in outpatient our Finally, prospective half-life public reimbursement which diagnostics, hospital the system. CMS they centers landscape developments expiration for serve. Gallium patients XX believe following Services, since including radiopharmaceutical proposals, several put pass-through have
to working adopt to to to industry maintain important that We simultaneously Act are our stakeholders working while CMS access proposal, and strongly this Congress patients ensure PYLARIFY. radiopharmaceuticals, the FIND pass advocate that innovative diagnostic including with with partners other
quarter men DEFINITY maintained year-over-year, continue with impact ultrasound-enhancing and the sales future microbubble prostate in the strong the XX.X% on leader about clear positive its and momentum million, are agent have to of second business, up we market the with living market. cancer. We $XX.X U.S. remain our In
was environment. to growth procedure year-over-year rebound post-pandemic health volume to overall as visits Contributing in in an this continued increase system as patients
the continued second our year. with help combined trends, programs promotional focus these of expect half and the to efforts We momentum on our in educational sustain
As work partner, targeted Mary PNTXXXX Biopharma therapeutics. chain, closely and and with commercial we our we expand POINT readiness. Anne to including To pipeline, progress to to radio this R&D, have realize our continue potential, mentioned, across continued supply portfolio manufacturing PSMA
expect PNTXXXX designation SPLASH, data pathway We randomized in has following this the the with registrational received year. who efficacy designed of Phase dosimetry, track three the is The and metastatic and with have or fast androgen read to top ARPI. study in to FDA evaluate line later from cancer prostate patients from treatment trial out safety follow-up. receptor phases: X SPLASH inhibitor, castrate-resistant progressed long-term treatment an and April
important imaging-based or analysis, central and endpoint or assessed were X:X by ARPI endpoint the receive a as leader, future information blinded randomized is like will to we either interim provide or review. radiographic analysis independent XX progression-free with safety an of enzalutamide. time survival, alternate survival our In patients The discussions, the FDA. for dosimetry abiraterone primary could XXX were total, At commenced SPLASH after therapies which primary perform which on overall PNTXXXX randomized. also with patient patients the
with collaboration US performed market As announced matured Point overall is estimated survival radiopharmaceuticals final billion. we sufficiently. When November, when PSMA analysis custom be total in have of we our oncology long-term will $X.X in addressable for data a studies,
sales amidst billion approved With PSMA the in be believe we this $X radiotherapy year, to set supply even market larger. this could disruptions, exceed
to progressing second Alzheimer's of the a is used we this men Needless half our agent to trials. I'm look XX than and of we disease to forward integration in completed this as biomarker Servo being for MKXXXX, with already which that top clinical a prostate clinical-stage more data cancer Technologies sharing in pet imaging PNTXXXX quarter, note line say, and asset for its year. to pleased
and to potential for in patient CAF staging treatments. future play the role imaging has important an selection patient
new proposed the from the the MKXXXX pet potential sharing look on Association and Alzheimer's that and and its Alzheimer's Aging how as donanemab. the by and incorporates We are the submission approval We of disease Institute guidelines diagnosis as in future. particularly progress National well of staging encouraged lecanemab forward and for more to regulatory on such therapies, as
collaboration biodistribution expressed modulate PET progressed also FAP Phase environment is the the tumor adult we micro radiation which I to XX fibroblasts, copper progression have specifically our Therapeutics, healthy in and with immune FAP agent. study volunteers. novel are over Ratio evaluating pharmacokinetics, imaging alpha-targeted In cancer-associated a dosimetry response. and believed initiated label tumor in in We
cancers, nearly The for stomach fat tumor in cancers, paired on ubiquitous wide tissues, cancer. epithelial-derived and the including lung variety breast, pancreatic, expression a makes of target across normal imaging with it to unique focus low expression of for all a
completion of study the patients. Following I in a we progress study, the plan cancer volunteer Phase to to healthy
call turn the for to update. a now over Bob financial will I
